Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.420 -0.080 (-5.33%)
Streaming Delayed Price Updated: 3:40 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2 3 4 Next >
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Appoints New Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Granted FDA Fast Track Designation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.